Yemarshet K. Gebreyohannes

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 214 citations

Medicine, Oncology, Pharmacology +10

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors

Yemarshet K. Gebreyohannes, Agnieszka Woźniak, Madalina-Elena Zhai et al. · Clinical Cancer Research · 2018 · 77 citations · Full text

Medicine, Oncology, Pharmacology +14

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

Jasmien Cornillie, Agnieszka Woźniak, H. Li et al. · Clinical & Translational Oncology · 2019 · 57 citations

Medicine, Cancer Biology, Oncology +8

Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing

Jasmien Cornillie, Agnieszka Woźniak, Haifu Li et al. · Molecular Cancer Therapeutics · 2019 · 39 citations · Full text

Veterinary Medicine, Cancer Biology, Oncology +17

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different <i>KIT</i> Mutations

Yemarshet K. Gebreyohannes, Patrick Schöffski, Thomas Van Looy et al. · Molecular Cancer Therapeutics · 2016 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17